The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant ...

The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing. But that relationship has deteriorated since then. ATP sued ...

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that ...

Detailed findings from a closely watched clinical trial hint that a new kind of drug may offer similar benefits as approved medicines in early Alzheimer’s disease, a result that could boost the ...

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among ...

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so ...

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox ...

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.